Eli Lilly and (LLY) financial statements
Eli Lilly and reported revenue of $65.2B in fiscal 2025, up 13.3% a year over 9 years.
Net income was $20.6B.
The diluted share count fell 15% over the period (buybacks).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Eli Lilly and's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.2B | $20.0B | $21.5B | $22.3B | $24.5B | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Cost of revenue | $5.7B | $4.4B | $4.7B | $4.7B | $5.5B | $7.3B | $6.6B | $7.1B | $8.4B | $11.1B |
| Gross profit | $15.5B | $15.5B | $16.8B | $17.6B | $19.1B | $21.0B | $21.9B | $27.0B | $36.6B | $54.1B |
| Research and development | $5.3B | $5.1B | $5.1B | $5.6B | $6.0B | $6.9B | $7.2B | $9.3B | $11.0B | $13.3B |
| Selling, general and admin | $6.5B | $6.0B | $6.0B | $6.2B | $6.1B | $6.4B | $6.4B | $7.4B | $8.6B | $11.1B |
| Interest expense | $185M | $225M | $242M | $401M | $360M | $340M | $332M | $486M | $781M | $895M |
| Pre-tax income | $3.4B | $2.3B | $3.7B | $5.3B | $7.2B | $6.2B | $6.8B | $6.6B | $12.7B | $25.7B |
| Income tax | $636M | $2.4B | $530M | $628M | $1.0B | $574M | $562M | $1.3B | $2.1B | $5.1B |
| Net income | $2.7B | -$204M | $3.2B | $8.3B | $6.2B | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| EPS (diluted) | $2.58 | -$0.19 | $3.13 | $8.89 | $6.79 | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Diluted shares | 1.06B | 1.05B | 1.03B | 936M | 913M | 912M | 905M | 903M | 904M | 899M |
| Gross margin | 73.1% | 77.7% | 78.2% | 78.8% | 77.7% | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% |
| Net margin | 12.9% | -1.0% | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
Balance sheet
Fiscal years, from Eli Lilly and's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $6.0B | $8.0B | $7.4B | $2.4B | $3.7B | $3.9B | $2.2B | $2.9B | $3.4B | $7.3B |
| Receivables | $4.0B | $4.5B | $4.6B | $4.5B | $5.9B | $6.7B | $6.9B | $9.1B | $11.0B | $17.8B |
| Inventory | $3.6B | $4.5B | $3.1B | $3.2B | $4.0B | $3.9B | $4.3B | $5.8B | $7.6B | $13.7B |
| Total current assets | $15.1B | $19.2B | $20.5B | $13.7B | $17.5B | $18.5B | $18.0B | $25.7B | $32.7B | $55.6B |
| Property, plant and equipment | $8.3B | $8.8B | $8.0B | $7.9B | $8.7B | $9.0B | $10.1B | $12.9B | $17.1B | $24.7B |
| Goodwill | $4.0B | $4.4B | $1.4B | $3.7B | $3.8B | $3.9B | $4.1B | $4.9B | $5.8B | $5.9B |
| Total assets | $38.8B | $45.0B | $43.9B | $39.3B | $46.6B | $48.8B | $49.5B | $64.0B | $78.7B | $112.5B |
| Total current liabilities | $11.0B | $14.5B | $11.9B | $11.8B | $12.5B | $15.1B | $17.1B | $27.3B | $28.4B | $35.2B |
| Long-term debt | $8.4B | $9.9B | $9.2B | $13.8B | $16.6B | $15.3B | $14.7B | $18.3B | $28.5B | $40.9B |
| Total liabilities | $24.7B | $33.3B | $33.0B | $36.6B | $40.8B | $39.7B | $38.7B | $53.1B | $64.4B | $85.9B |
| Shareholders' equity | $14.0B | $11.6B | $9.8B | $2.6B | $5.6B | $9.0B | $10.6B | $10.8B | $14.3B | $26.5B |
| Net debt | $5.7B | $7.1B | $3.0B | $13.0B | $12.9B | $13.1B | $14.2B | $22.4B | $30.4B | $35.2B |
Cash flow
Fiscal years, from Eli Lilly and's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.9B | $5.6B | $5.5B | $4.8B | $6.5B | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| Stock-based compensation | $255M | $281M | $280M | $312M | $308M | $343M | $371M | $629M | $646M | $626M |
| Dividends paid | $2.2B | $2.2B | $2.3B | $2.4B | $2.7B | $3.1B | $3.5B | $4.1B | $4.7B | $5.4B |
| Share buybacks (net) | -$600M | -$300M | -$4.2B | -$4.4B | -$500M | -$1.2B | -$1.5B | -$750M | -$2.5B | -$4.1B |
| Net borrowing | $2.5B | $3.0B | -$729M | $4.7B | $292M | $501M | -$62M | $8.7B | $8.9B | $8.1B |
| Dividends per share | $2.03 | $2.08 | $2.24 | $2.58 | $2.94 | $3.39 | $3.91 | $4.50 | $5.18 | $5.99 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LLY.
Open LLY in InvestinglyQuestions
What was Eli Lilly and's revenue in 2025?
$65.2B in fiscal 2025, from its 10-K filing.
From Eli Lilly and's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.